Riskpilot← Back to searchSign inGet full accessEngman Medical AB
ABIn liquidationOrg 5592845977UmeåBeauty care and other beauty treatment activities · NACE 9622Est. 20200 employees
Revenue 2025
SEK -1
-100% vs 2024
EBITDA margin
2603000.0%
+71% vs 2024
Equity ratio
11.9%
Financial strength
Net profit 2025
SEK -27K
+55% vs 2024
| Revenue | SEK -1 | -100% |
| EBITDA | SEK -26K | +71% |
| Net profit | SEK -27K | +55% |
| Total assets | SEK 16K | -20% |
| Equity | SEK 2K | -86% |
| Employees | 0 | — |
Legal name
Engman Medical AB
Org number
5592845977
Legal form
Aktiebolag
NACE code
9622 · Beauty care and other beauty treatment activities
Founded
20 november 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-10-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn Firman tecknas var för sig av externa firmatecknarna
Company purpose
Estetiska injektionsbehandlingar med botulinomtoxin och filler. Medicinska hudvårdvårdsbehandlingar. Skönhetsvård på egen salong, samt hemma hos kunder. Försäljning av hudvård och skönhetsprodukter. Uthyrning av mig själv som distriktsköterska, arbetsledare, specialistsjuksköterska, utbildare och konsultation inom vård och omsorg. Uppdrag tas enskilt eller genom bemanningsföretag. Allt som rör jakt och viltvård. Jordbruksarbete samt skogsarbete.Jakt och eftersöksverksamhet. Hundarbete och omsorg, hunduppfödning. Inköp och försäljning av hundartiklar, hundfoder,jakt- och fiskekläder och artiklar. Hantverk inom trofémontering. Viltköttshantering och förmedling av kött. Försäljning av jakter, guidning och friluftsupplevelser. Utbildning och konsultverksamhet inom jakt, skytte, viltvård, skog, jägarexamen, fiske och hund. Samt därmed förenlig verksamhet.
Address
Umeå
Email
info@heinestams.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 164 | 269 | 464 | 417 | −0 |
| Staff expenses | — | −62 | −298 | −436 | −0 |
| EBITDA | −2 | 54 | 50 | −91 | −26 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −2 | 54 | 50 | −91 | −26 |
| Net financials | −1 | −0 | −0 | −1 | −1 |
| Profit before tax | −3 | 39 | 33 | −61 | −27 |
| Tax | −0 | −9 | −10 | — | — |
| Net profit | −3 | 29 | 23 | −61 | −27 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 48 | 110 | 149 | 20 | 16 |
| Equity | 32 | 62 | 85 | 13 | 2 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 15 | 34 | 34 | 7 | 14 |
| Total debt | 15 | 34 | 34 | 7 | 14 |
EBITDA margin
-2603000.0%
This company
15.8%
Market median
-16474784% vs market
20212025
Equity ratio
11.9%
This company
38.2%
Market median
-69% vs market
20212025
Return on equity
-1428.8%
This company
18.4%
Market median
-7865% vs market
20212025
Net profit margin
-2737500.0%
This company
8.1%
Market median
-33796396% vs market
20212025
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
7.42×
This company
0.62×
Market median
-1097% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-11-01 – 2025-10-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-11-01 – 2024-10-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-11-01 – 2023-10-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-11-01 – 2022-10-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-11-01 – 2021-10-31
| Name | Role | Member since |
|---|---|---|
| Current (7) | ||
EJ External Signatory | External Signatory | 2025 |
SM External Signatory | External Signatory | 2025 |
SM External Signatory | External Signatory | 2025 |
EF External Signatory | External Signatory | 2025 |
MV Liquidator | Liquidator | 2025 |
AB External Signatory | External Signatory | 2025 |
AE External Signatory | External Signatory | 2025 |
| Former (2) | ||
HM Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 – 2025 |
KI Chief Executive Officer | Chief Executive Officer | 2022 – 2025 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Engman Medical AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Emma Johanna Åström | External Signatory | 0 companies |
| Sofie Margareta Lundberg | External Signatory | 0 companies |
| Susanne Margareta Fransson | External Signatory | 0 companies |
| Emma Frida Ramona Melander Vängbo | External Signatory | 0 companies |
| Mona Veronica Vesterberg | Liquidator | 0 companies |
| Anna Birgitta Emanuelsson | External Signatory | 0 companies |
| Anna Elisabeth Adolfsson | External Signatory | 0 companies |
| Hans Marcus Engman | Deputy Chief Executive Officer | 0 companies |
| Karin Ida Helena Engman | Chief Executive Officer | 0 companies |